Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
0.8132
-0.0267 (-3.18%)
At close: Nov 6, 2026, 4:00 PM EST
0.8500
+0.0368 (4.53%)
After-hours: Nov 6, 2026, 7:30 PM EST
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $45.46M in the quarter ending September 30, 2026, a decrease of -69.87%. This brings the company's total for the last twelve months to $352.05M, down -24.33% year-over-year. In the year 2025, Organogenesis Holdings had annual revenue of $564.17M with 17.04% growth. That makes Organogenesis Holdings the 13,434th largest company in the world by revenue and 2,509th in the United States.
Revenue (ttm)
$352.05M
Revenue Growth
-24.33%
P/S Ratio
0.30
Revenue / Employee
$412,233
Employees
854
Market Cap
105.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 564.17M | 82.13M | 17.04% |
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organigram Global | 217.71M |
| Akebia Therapeutics | 197.20M |
| Glass House Brands | 176.98M |
| Anika Therapeutics | 123.43M |
| ADC Therapeutics | 79.58M |
| Journey Medical | 68.18M |
| BGM Group | 47.90M |
| Cumberland Pharmaceuticals | 44.30M |
ORGO News
- 3 days ago - Organogenesis Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Organogenesis Holdings Earnings release: Q3 2026 - Filings
- 3 days ago - Organogenesis Holdings Quarterly report: Q3 2026 - Filings
- 3 days ago - Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 27 days ago - Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers - GlobeNewsWire
- 27 days ago - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 - GlobeNewsWire
- 6 weeks ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 3 months ago - Organogenesis price target lowered to $2 from $3 at Truist - TheFly